DNAprint Genomics (DNAG)

[mingwan0]

Carter

Not being a medical professional I bow to your superior knowledge. I did mean sulfonamide as a class of drug. One other thing to say is that there are multiple ACE inhibitors/ARBa, and it is quite possible to get to the magic number of 21 with statins and ACE inhibitors/ARBs alone.

From reading the statin patent application it seems that a main portion of response/non-response for any class of drugs can be determined from a set of SNPs, and they then overlay this with other SNPs specific to individual drugs. This is logical given that a given class of drugs should conceivably share a common mechanism. It might also be the case that for some classes of drugs the variability in response in individual drugs is not as great as with other classes. Therefore, it is certainly possible that they could quickly move ahead on multiple fronts in development - even if the apparent lead time for such development based on work on statins seems to be relatively long.

At the end of the day I don't care what exactly is being tested at this stage, as long as they end up with classifiers that can be used for up to 21 drugs. It would be nice to know which ones have been worked on or are being worked on, but we will find out eventually soon as the clinical trial details are public domain. The mere fact that we have effective classifiers puts us a long way ahead of everybody else as (leaving aside things that determine genetic basis for an aspect of drug metabolism e.g. cytochrome P450) I am not aware of any classifiers on the market or at similar stages of development.